Graphite Bio presents preclinical data for sequencing method to measure gene editing outcomes in sickle cell

LENZ Therapeutics, Inc.

Preclinical data presented at ASH on single-cell RNA sequencing method to assess gene correction in reticulocytes.
Method accurately differentiated AA, AS, and SS reticulocytes in proof-of-concept mixtures.
Method will be used to measure gene editing outcomes in patients treated with nula-cel (GPH101) for sickle cell disease.
Nula-cel is being evaluated in the CEDAR Phase 1/2 trial with Fast Track and Orphan Drug designations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.